keyword
MENU ▼
Read by QxMD icon Read
search

Cornel transplant

keyword
https://www.readbyqxmd.com/read/27864161/maintenance-versus-induction-therapy-choice-on-outcomes-after-autologous-transplantation-for-multiple-myeloma
#1
Robert F Cornell, Anita D'Souza, Adetola A Kassim, Luciano J Costa, Racquel D Innis-Shelton, Mei-Jie Zhang, Jiaxing Huang, Muneer Abidi, Jack Aiello, Gorgun Akpek, Asad Bashey, Qaiser Bashir, Jan Cerny, Raymond Comenzo, Miguel Angel Diaz, César Freytes, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Shahrukh Hashmi, Leona Holmberg, Nasheed Hossain, Rammurti T Kamble, Mohamed Kharfan-Dabaja, Tamila Kindwall-Keller, Robert Kyle, Shaji Kumar, Hillard Lazarus, Cindy Lee, Angelo Maiolino, David I Marks, Kenneth Meehan, Joe Mikhael, Rajneesh Nath, Taiga Nishihori, Richard F Olsson, Muthalagu Ramanathan, Ayman Saad, Sachiko Seo, Saad Usmani, David Vesole, Ravi Vij, Dan Vogl, Baldeep M Wirk, Jean Yared, Amrita Krishnan, Tomer Mark, Yago Nieto, Parameswaran Hari
Bortezomib (V), lenalidomide (R), cyclophosphamide (C) and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens prior to autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the US. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008-2013...
November 15, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27862883/the-banff-2015-kidney-meeting-report-current-challenges-in-rejection-classification-and-prospects-for-adopting-molecular-pathology
#2
A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, B J Nankivell, R B Colvin, M Afrouzian, E Akalin, N Alachkar, S Bagnasco, J U Becker, L Cornell, C Drachenberg, D Dragun, H De Kort, I W Gibson, E S Kraus, C Lefaucheur, C Legendre, H Liapis, T Muthukumar, V Nickeleit, B Orandi, W Park, M Rabant, P Randhawa, E F Reed, C Roufosse, S V Seshan, B Sis, H K Singh, C Schinstock, A Tambur, A Zeevi, M Mengel
The XIII. Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection, requires further consensus agreement and validation in biopsies...
November 10, 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/27832003/development-of-a-model-of-pediatric-lung-failure-pathophysiology
#3
John M Trahanas, Fares Alghanem, Catalina Ceballos-Muriel, Hayley R Hoffman, Alice Xu, Kristopher B Deatrick, Marie Cornell, Alvaro Rojas-Pena, Robert H Bartlett, Ronald B Hirschl
A pediatric artificial lung (PAL) is under development as a bridge to transplantation or lung remodeling for children with end-stage lung failure (ESLF). In order to evaluate the efficiency of a PAL, a disease model mimicking the physiologic derangements of pediatric ESLF is needed. Our previous right pulmonary artery ligation (rPA-LM) ovine model achieved that goal, but caused immediate mortality in nearly half of the animals. In this study, we evaluated a new technique of gradual postoperative right pulmonary artery (rPA) occlusion using a Rummel tourniquet (rPA-RT) in seven (25-40 Kg) sheep...
November 9, 2016: ASAIO Journal: a Peer-reviewed Journal of the American Society for Artificial Internal Organs
https://www.readbyqxmd.com/read/27789362/allogeneic-transplantation-for-relapsed-waldenstr%C3%A3-m-macroglobulinemia-and-lymphoplasmacytic-lymphoma
#4
Robert F Cornell, Veronika Bachanova, Anita D'Souza, Kwang Woo-Ahn, Michael Martens, Jiaxing Huang, A Samer Al-Homsi, Saurabh Chhabra, Edward Copelan, Miguel-Angel Diaz, Cesar O Freytes, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Gerhard Hildebrandt, Rammurti T Kamble, Mohamed Kharfan-Dabaja, Tamila Kindwall-Keller, Hillard M Lazarus, David I Marks, Taiga Nishihori, Richard F Olsson, Ayman Saad, Saad Usmani, David H Vesole, Jean Yared, Tomer Mark, Yago Nieto, Parameswaran Hari
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) is characterized by lymphoplasmacytic proliferation, lymph node and spleen enlargement, bone marrow involvement, and IgM production. Treatment varies based on the extent and biology of disease. In some patients, the use of allogeneic hematopoietic cell transplantation (alloHCT) may have curative potential. We evaluated long-term outcomes of 144 patients who received adult alloHCT for WM/LPL. Data were obtained from the Center for International Blood and Marrow Transplant Research database (2001 to 2013)...
October 24, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27478873/multiplexed-nanoplasmonic-temporal-profiling-of-t-cell-response-under-immunomodulatory-agent-exposure
#5
Bo-Ram Oh, Pengyu Chen, Robert Nidetz, Walker McHugh, Jianping Fu, Thomas P Shanley, Timothy T Cornell, Katsuo Kurabayashi
Immunomodulatory drugs-agents regulating the immune response-are commonly used for treating immune system disorders and minimizing graft versus host disease in persons receiving organ transplants. At the cellular level, immunosuppressant drugs are used to inhibit pro-inflammatory or tissue-damaging responses of cells. However, few studies have so far precisely characterized the cellular-level effect of immunomodulatory treatment. The primary challenge arises due to the rapid and transient nature of T-cell immune responses to such treatment...
July 22, 2016: ACS Sensors
https://www.readbyqxmd.com/read/27225518/early-subclinical-inflammation-correlates-with-outcomes-in-positive-crossmatch-kidney-allografts
#6
Patrick G Dean, Walter D Park, Lynn D Cornell, Carrie A Schinstock, Mark D Stegall
The aim of this study was to investigate correlations between early subclinical findings (10- and 90-day histology and gene expression data) and late outcomes (transplant glomerulopathy and graft loss) in positive crossmatch kidney transplants (+XMKTx). We compared 34 +XMKTx (19 receiving eculizumab and 15 receiving standard of care without eculizumab) to 13 -XMKTx (between August 2001 and August 2011). At 10 days, light microscopy identified subclinical inflammation in only 18% of +XMKTx, while intragraft gene expression identified inflammation in 79% (gene sets for activated macrophages, dendritic cells, NK cells or T cells)...
August 2016: Clinical Transplantation
https://www.readbyqxmd.com/read/27168578/magnetic-nanoparticles-as-a-potential-vehicle-for-corneal-endothelium-repair
#7
Lauren E Cornell, Jenny L Wehmeyer, Anthony J Johnson, Mauris N Desilva, David O Zamora
The corneal endothelium is paramount to the health and function of the cornea as damage to this cell layer can lead to corneal edema, opacification, and ultimately vision loss. Transplantation of the corneal endothelium is associated with numerous limitations, including graft rejection, thus an alternative therapeutic treatment is needed to restore endothelial layer integrity. We hypothesize that a nanotechnology-based approach using superparamagnetic iron oxide nanoparticles (SPIONPs) can ultimately be used to guide corneal endothelial cells (CECs) to injured areas via an external magnetic force without changing their morphology or viability...
May 2016: Military Medicine
https://www.readbyqxmd.com/read/27017874/temporal-igg-subtype-changes-in-recurrent-idiopathic-membranous-nephropathy
#8
A G Kattah, M P Alexander, A Angioi, A S De Vriese, S Sethi, F G Cosio, E C Lorenz, L D Cornell, F C Fervenza
Determination of the IgG subtypes within the immune deposits in membranous nephropathy (MN) may be helpful in the differential diagnosis. IgG4 is the predominant subtype in idiopathic MN and recurrent MN, while IgG1, IgG2, and IgG3 subtypes are more common in secondary MN and de novo disease in the allograft. The temporal change of IgG subclasses in individual patients and its correlation with clinical variables have not been studied. We reviewed all posttransplantation protocol and indication biopsies (49) in 18 patients with recurrent MN who underwent transplantation at our center between 1998 and 2013 and performed IgG subtyping (IgG1-4)...
October 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/26819055/early-th1-immunity-promotes-immune-tolerance-and-may-impair-graft-versus-leukemia-effect-after-allogeneic-hematopoietic-cell-transplantation
#9
LETTER
Brian G Engelhardt, Sophie Paczesny, Dae Kwang Jung, Etienne Daguindau, Madan Jagasia, Bipin N Savani, Wichai Chinratanalab, Robert F Cornell, Stacey Goodman, John P Greer, Adetola A Kassim, Salyka Sengsayadeth, Sandra M Yoder, Michael T Rock, James E Crowe
No abstract text is available yet for this article.
May 2016: Haematologica
https://www.readbyqxmd.com/read/26726946/evolving-paradigms-in-the-treatment-of-relapsed-refractory-multiple-myeloma-increased-options-and-increased-complexity
#10
REVIEW
R F Cornell, A A Kassim
The use of modern therapies such as thalidomide, bortezomib and lenalidomide coupled with upfront high-dose therapy and autologous stem cell transplant (ASCT) has resulted in improved survival in patients with newly diagnosed multiple myeloma (MM). However, patients with relapsed/refractory multiple myeloma (RRMM) often have poorer clinical outcomes and might benefit from novel therapeutic strategies. Emerging therapies, such as deacetylase inhibitors, monoclonal antibodies and new proteasome inhibitors, appear promising and may change the therapeutic landscape in RRMM...
April 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26524732/comparison-of-subcutaneous-versus-intravenous-alemtuzumab-for-graft-versus-host-disease-prophylaxis-with-fludarabine-melphalan-based-conditioning-in-matched-unrelated-donor-allogeneic-stem-cell-transplantation
#11
Khilna Patel, Sapna Parmar, Shreya Shah, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Koen van Besien
The objective of this study was to compare infusion-related reactions and outcomes of using subcutaneous (subQ) alemtuzumab versus intravenous (i.v.) alemtuzumab as graft-versus-host disease (GVHD) prophylaxis for matched unrelated donor stem cell transplantations. Outcomes include incidence of cytomegalovirus (CMV)/Epstein-Barr (EBV) viremia, development of CMV disease or post-transplantation lymphoproliferative disorder, fatal infections, acute and chronic GVHD, time to engraftment, relapse rate, and survival...
March 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/26491413/a-special-meeting-review-edition-highlights-in-the-treatment-of-hepatitis-c-virus-from-the-2014-liver-meeting-a-review-of-selected-presentations-from-the-2014-liver-meeting-november-7-11-2014-%C3%A2-boston-massachusettsspecial-reporting-on-%C3%A2-evaluation-of-sofosbuvir
#12
A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York.
(no author information available yet)
No abstract text is available yet for this article.
December 2014: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/26371138/improved-outcomes-after-autologous-hematopoietic-cell-transplantation-for-light-chain-amyloidosis-a-center-for-international-blood-and-marrow-transplant-research-study
#13
Anita D'Souza, Angela Dispenzieri, Baldeep Wirk, Mei-Jie Zhang, Jiaxing Huang, Morie A Gertz, Robert A Kyle, Shaji Kumar, Raymond L Comenzo, Robert Peter Gale, Hillard M Lazarus, Bipin N Savani, Robert F Cornell, Brendan M Weiss, Dan T Vogl, César O Freytes, Emma C Scott, Heather J Landau, Jan S Moreb, Luciano J Costa, Muthalagu Ramanathan, Natalie S Callander, Rammurti T Kamble, Richard F Olsson, Siddhartha Ganguly, Taiga Nishihori, Tamila L Kindwall-Keller, William A Wood, Tomer M Mark, Parameswaran Hari
PURPOSE: Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high risk of early mortality (EM). In a multicenter randomized comparison against oral chemotherapy, autotransplantation was associated with 24% EM. We analyzed trends in outcomes after autologous hematopoietic cell transplantation for AL in North America. PATIENTS AND METHODS: Between 1995 and 2012, 1,536 patients with AL who underwent autotransplantation at 134 centers were identified in the Center for International Blood and Marrow Transplant Research database...
November 10, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26327628/engraftment-syndrome-after-autologous-stem-cell-transplantation-an-update-unifying-the-definition-and-management-approach
#14
REVIEW
Robert Frank Cornell, Parameswaran Hari, William R Drobyski
Engraftment syndrome (ES) encompasses a continuum of periengraftment complications after autologous hematopoietic stem cell transplantation. ES may include noninfectious fever, skin rash, diarrhea, hepatic dysfunction, renal dysfunction, transient encephalopathy, and capillary leak features, such as noncardiogenic pulmonary infiltrates, hypoxia, and weight gain with no alternative etiologic basis other than engraftment. Given its pleiotropic clinical presentation, the transplant field has struggled to clearly define ES and related syndromes...
December 2015: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/26301967/contribution-of-chemotherapy-mobilization-to-disease-control-in-multiple-myeloma-treated-with-autologous-hematopoietic-cell-transplantation
#15
MULTICENTER STUDY
G L Uy, L J Costa, P N Hari, M-J Zhang, J-X Huang, K C Anderson, C N Bredeson, N S Callander, R F Cornell, M A D Perez, A Dispenzieri, C O Freytes, R P Gale, A Garfall, M A Gertz, J Gibson, M Hamadani, H M Lazarus, M E Kalaycio, R T Kamble, M A Kharfan-Dabaja, A Y Krishnan, S K Kumar, R A Kyle, H J Landau, C H Lee, A Maiolino, D I Marks, T M Mark, R Munker, T Nishihori, R F Olsson, M Ramanathan, T E Rodriguez, A A Saad, B N Savani, G J Schiller, H C Schouten, J R Schriber, E Scott, S Seo, M Sharma, S Ganguly, E A Stadtmauer, J Tay, L B To, D H Vesole, D T Vogl, J L Wagner, B Wirk, W A Wood, A D'Souza
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012...
December 2015: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26274817/changing-kidney-allograft-histology-early-posttransplant-prognostic-implications-of-1-year-protocol-biopsies
#16
F G Cosio, M El Ters, L D Cornell, C A Schinstock, M D Stegall
Allograft histology 1 year posttransplant is an independent correlate to long-term death-censored graft survival. We assessed prognostic implications of changes in histology first 2 years posttransplant in 938 first kidney recipients, transplanted 1999-2010, followed for 93.4 ± 37.7 months. Compared to implantation biopsies, histology changed posttransplant showing at 1 year that 72.6% of grafts had minor abnormalities (favorable histology), 20.2% unfavorable histology, and 7.2% glomerulonephritis. Compared to favorable, graft survival was reduced in recipients with unfavorable histology (hazards ratio [HR] = 4...
January 2016: American Journal of Transplantation
https://www.readbyqxmd.com/read/26191950/minimal-residual-disease-testing-after-stem-cell-transplantation-for-multiple-myeloma
#17
REVIEW
A M Sherrod, P Hari, C A Mosse, R C Walker, R F Cornell
Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sensitive methods to measure or detect such disease have been evaluated, including multi-parametric flow cytometry, PCR, next-generation sequencing and imaging modalities. The following literature review examines current methods for detecting and monitoring minimal or measurable residual disease (MRD) in the post-transplant setting...
January 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/26138032/organ-procurement-organizations-and-the-electronic-health-record
#18
R J Howard, L D Cochran, D L Cornell
The adoption of electronic health records (EHRs) has adversely affected the ability of organ procurement organizations (OPOs) to perform their federally mandated function of honoring the donation decisions of families and donors who have signed the registry. The difficulties gaining access to potential donor medical record has meant that assessment, evaluation, and management of brain dead organ donors has become much more difficult. Delays can occur that can lead to potential recipients not receiving life-saving organs...
October 2015: American Journal of Transplantation
https://www.readbyqxmd.com/read/25915809/bortezomib-based-induction-for-transplant-ineligible-al-amyloidosis-and-feasibility-of-later-transplantation
#19
R F Cornell, X Zhong, C Arce-Lara, E Atallah, L Blust, W R Drobyski, T S Fenske, M C Pasquini, J D Rizzo, W Saber, P N Hari
Recent studies support the use of bortezomib-based therapies in light chain amyloidosis (AL). We performed a retrospective analysis of the safety, efficacy and long-term survival (median follow-up 3 years) after bortezomib-based treatment in 28 consecutive patients with de novo AL deemed ineligible at initial presentation. The first 14 patients received bortezomib and dexamethasone (VD), and the second 14 patients received cyclophosphamide, bortezomib and dexamethasone (CVD; CyBorD). Both regimens were well tolerated with no treatment-related mortality...
July 2015: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/25905984/intravitreal-antivascular-endothelial-growth-factor-therapy-may-induce-proteinuria-and-antibody-mediated-injury-in-renal-allografts
#20
Wisit Cheungpasitporn, Fouad T Chebib, Lynn D Cornell, Michelle L Brodin, Samih H Nasr, Carrie A Schinstock, Mark D Stegall, Hatem Amer
INTRODUCTION: Systemic adverse effects of intravenous antivascular endothelial growth factor (VEGF) therapy include: hypertension, proteinuria, renal failure, and thrombotic microangiopathy. Intravitreal therapy with these agents is generally believed to be safe. METHODS: We report 2 cases of renal transplant recipients who developed significant allograft dysfunction after the initiation of intravitreal anti-VEGF therapy. RESULTS: The first case is a 67-year-old man with polycystic kidney disease and recipient of a zero-antigen mismatch kidney allograft which developed worsening proteinuria over the first year after transplantation...
November 2015: Transplantation
keyword
keyword
40019
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"